DDInter1532 DDInter927
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Promazine {u} (Compound) resembles {v} (Compound) Propiomazine
Promazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Promazine {u} (Compound) binds {v} (Gene) ADRA2A
Promazine {u} (Compound) upregulates {v} (Gene) EBP
Promazine {u} (Compound) downregulates {v} (Gene) EZH2
Promazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Promazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Promazine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Promazine (Compound) resembles Propiomazine (Compound)
Promazine (Compound) resembles Ethopropazine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Promazine (Compound) binds ADRA2A (Gene)
Promazine (Compound) upregulates EBP (Gene)
Promazine (Compound) downregulates EZH2 (Gene)
Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Promazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Promazine may lead to a major life threatening interaction when taken with Bupropion